United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

Download PDF Copy

Reviewed

United Therapeutics CorporationMar 26 2014

United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin^® (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost™ by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with United Therapeutics.

"We are grateful for Mochida's diligent work in obtaining this approval in Japan," said Yu-Lun Lin, United Therapeutics' Associate Vice President and Managing Director, UTAsia. "We look forward to Mochida's launch of Treprost and to bringing this new therapeutic option to the PAH community in Japan."

Source:

United Therapeutics Corporation

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

Experts chart path to bring microbiome science into routine clinical care

Synthetic Biology and the Pursuit of Living Diagnostics and Therapeutics

Scientists use AI to build mutation-proof antibodies for SARS-CoV-2

Scaling B-cell cloning workflows for antibody development

How microRNA is transforming science: From discovery to diagnostics

Can microbiome discoveries finally become treatments? Scientists show the way

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.